Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of 426c.Mod.Core-C4b Priming and BG505 SOSIP.GT1.1 gp140 Boost in Healthy Adults
NCT05471076Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2022
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of 426c.Mod.Core-C4b and BG505 SOSIP GT1.1 gp140 in human immunodeficiency virus infection (HIV) (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of participants showing local vaccination reactogenicity signs and symptoms, Number of participants showing systemic vaccination reactogenicity signs and symptoms and 6 more. Started Aug 2022; status: completed.
02
Drugs
426c.Mod.Core-C4bBG505 SOSIP GT1.1 gp140
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05471076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471076.